Our Executive Management

Ms. Zannes brings more than 30 years of executive-level management experience dedicated to defining and advancing company goals and overcoming obstacles impeding corporate success. Prior to her position at bioAffinity Technologies, Ms. Zannes founded The Zannes Firm focusing on strategic solutions for private industry in the medical, environmental and energy fields. In her current capacity as bioAffinity Technologies CEO and President, she has built a team of award-winning scientists and executives who are advancing breakthrough oncology-focused diagnostics and therapeutics.

 

Ms. Zannes was President of the Energy Recovery Council, the national trade group for the $10 billion waste-to-energy industry, and General Manager of ECOS Corporation, a subsidiary of Burlington Environmental. Ms. Zannes also served as a project manager at Wheelabrator Technologies, Inc. where she led project teams that developed, negotiated and financed the company’s renewable energy generation facilities. Ms. Zannes began her career as a journalist, working for Voice of America and the Associated Press. Before entering the business world, she served as a legislative aide specializing in energy policy and law for Congressman Charles Wilson (D-TX). She is licensed to practice law in New Mexico. She has been awarded Lifetime Achievement Awards by the American Society of Mechanical Engineers and the Earth Engineering Center Award from the WTE Council of Columbia University.

 

She is the co-founder of two engineering research centers at Columbia University. Ms. Zannes received her B.A. in Journalism from the University of New Mexico and her J.D. from the University of Puget Sound in Washington State.

 

Inventions under Patent Protection

Mr. Zannes has been corporate legal counsel to both public and private biomedical firms for more than 16 years, having begun his legal career as a sole practitioner accepting criminal, business, family, and tort litigation. Prior to receiving his J.D., Mr. Zannes was a court bailiff and ran his own private investigation firm after serving as an investigator for the Albuquerque City Attorney. He received his J.D. from the University of New Mexico School of Law and attended the New England Conservatory with studies in violin and saxophone. Mr. Zannes began his undergraduate education at The University of North Carolina where he was a student athlete on scholarship. In addition to his duties as General Counsel and Secretary, Mr. Zannes is responsible for corporate compliance and directs Human Resources. Mr. Zannes and Maria Zannes are siblings.

Dr. Rebel is a cancer (stem) cell biologist, with more than 20 years of experience in scientific research, focused on understanding the molecular events that lead to cancer development.  She received her M.D. and Ph.D. from the Free University in Amsterdam, The Netherlands, and post-doctoral training at the Dana-Farber Cancer Institute, Harvard Medical School.  From 2005 to 2016, she led her own research group at The University of Texas (UT) Health Science Center at San Antonio, where she first collaborated with bioAffinity.  Dr. Rebel received the 2012 Cancer Therapy and Research Center Discovery of the Year Award.  She is the (co)author of more than 40 publications in peer-reviewed journals.

 

Dr. Rebel’s Publications >>

 

Patents under Patent Protection
WO/2019/200403
WO/2017/218959

Dr. Bauta is a medicinal chemist with more than 25 years of experience in discovery, development and commercialization of pharmaceuticals to treat oncology, virology, neuroscience, immunology and metabolic diseases. He joins bioAffinity Technologies from Southwest Research Institute where he helped develop the Institute’s pharmaceuticals services and bioengineering business. Dr. Bauta was Associate Director of Science at Genzyme Corporation and held a similar position at Ilex Products, Inc., where he was responsible for the discovery, development and FDA approval of multiple therapeutics. He holds several patents and has published in the journal Science and more than a dozen other scientific journals and conference proceedings. Dr. Bauta received his Ph.D. from the University of Chicago.

 

Dr. Bauta’s Publications >>

 

Inventions under Patent Protection

Mr. Edwards has more than 20 years of extensive experience in corporate finance and accounting, and has been providing CFO consulting services to biotechnology companies for the past eight years. Most recently, he was the CFO for CytoBioscience and previously he was the CFO for OncoVista Innovative Therapies. He was an assistant controller at ILEX Oncology, and controller at Bionumerik Pharmaceuticals and U.S. Global Investors. Mr. Edwards started his career at PricewaterhouseCoopers. He is a Certified Public Accountant and holds a Bachelor’s degree in business administration from The University of Texas at San Antonio and a Master’s degree from The University of Texas.

Dr. Rebeles brings 18 years of research experience to her work with bioAffinity where she directs the research and development of our porphyrin-based cancer diagnostics and has extensive experience in flow cytometry. She was Technical Director of the Flow Cytometry and Microarray Core at the Greehey Children’s Cancer Research Institute, and received her Masters degree in Biology at the University of Texas at San Antonio. She earned her Ph.D. in Nutritional Biochemistry from the University of North Carolina at Chapel Hill where she investigated the role of metabolism on immunity to infectious disease. Her previous position as a research scientist with the United States Air Force 59th Medical Wing included responsibility for identifying critical gaps in military medicine and scientific support for multiple research projects. Dr. Rebeles has published seven peer-reviewed papers, a book chapter, with several papers in preparation and holds multiple honors.

Jennifer Rebeles Publications >>

Mr. Reveles brings more than 25 years of experience as a clinical geneticist skilled in the creation and management of CLIA clinical laboratories, coding and CPT reimbursement valuations.  Mr. Reveles is board certified by the American Society of Clinical Pathology as a clinical specialist in cytogenetics. He was Laboratory Director for OncoPath Laboratory – START Cancer Center in San Antonio, Texas.  Mr. Reveles is (co)author of 15 publications and three abstracts in peer-reviewed journals.  He earned his Master’s Degree in biology/genetics from the University of The Incarnate Word in San Antonio, Texas.

 

Xavier T. Revels Publications >>

Our Board of Directors

Steven Girgenti is a veteran healthcare executive with a foundation of expertise in healthcare marketing strategies, financing and mergers and acquisitions. Steve has been Executive Chairman of bioAffinity Technologies, Inc. since November 2014. He is presently the Managing Partner of Medi-Pharm Consulting, LLC providing strategic services to medical device, pharmaceutical and diagnostic businesses. Steve was formerly CEO and co-founder of DermWorx Incorporated, a dermatology company that specialized in developing nanotechnology formulations to enhance the performance of topical drugs. Mr. Girgenti was also the founder and CEO of Healthworld Corporation until 2008, a leading global healthcare marketing services network with 55 offices in 36 countries. The network had more than 1,000 brand assignments from nearly 200 clients worldwide, providing strategic marketing and communications services to many of the world’s leading healthcare companies. Mr. Girgenti founded Healthworld in 1986 and, under his leadership, the company made numerous acquisitions to expand and diversify the business. Healthworld went public in 1997. In 1998, and again in 1999, Business Week named Healthworld one of the “Best Small Corporations in America”. In 1999, Forbes listed Healthworld as one of the “200 Best Small Companies”. Mr. Girgenti was recognized as “Entrepreneur of the Year” by NASDAQ in 1999, and was named Med Ad News’ first “Medical Advertising Man of the Year” in 2000. In 2010 he was inducted into the Medical Advertising Hall of Fame. In addition, Mr. Girgenti is Vice Chairman of the Board of Governors for the Mt. Sinai Hospital Prostate Disease and Research Center in New York City, and is on the Board of Directors for the Jack Martin Fund, a Mt. Sinai Hospital affiliated charitable organization devoted to pediatric oncology research. He graduated from Columbia University and has worked in the pharmaceutical industry since 1968 for companies such as Bristol-Myers Squibb, Carter Wallace and DuPont.

Mr. Anderson has more than 40 years of broad experience the healthcare industry in which he held executive positions at CIBA, Becton Dickinson, Pfizer, Warner Lambert-Parke-Davis, Schering Plough and Centocor.   Mr. Anderson was Vice-President of Marketing for the Key Pharmaceuticals division of Schering-Plough and later at Centocor, a worldwide healthcare company now owned by Johnson & Johnson.  Mr. Anderson sat on the Executive Committee of Physicians World Communications Group (PWCG), where he was appointed as a Partner and Chief Operating Officer of the Company.  Mr. Anderson currently provides Executive Management services to a number of CEOs of healthcare companies.  Mr. Anderson received a B.A. in political science from Rutgers University and is a MENSA member.

Mr. Rubin, a Certified Public Accountant, serves as a Managing Member of Masters Research Partners, LLC, an investment Fund of Hedge Funds that he co-founded in October 2000. Mr. Rubin began his career with Deloitte & Touche and later served as Managing Partner at Schissel, Rubin & Lehman, a New York based Certified Public Accounting firm. He has been involved in the investment business, including hedge funds, private equity and investment banking, for more than 20 years. Mr. Rubin is active in numerous charities as well as his Family’s foundation, and presently serves on the Board of Boca Raton Regional Hospital Foundation and the Finance committee of the Levitz Jewish Community Center, as well as serving as a Board Member for Family Promise of the Federation of South Palm Beach County. He graduated with a Bachelor of Science cum laude from SUNY at Buffalo, New York.

Peter S. Knight is a Partner at Cyan Capital Partners, a Fund dedicated to helping new Fund managers and asset owners in the field of sustainable investing. Prior to that, Peter was a Founding Partner at Generation Investment Management, where he helped build, with his partners Al Gore and David Blood, a leading global sustainable investing firm with assets under management now exceeding $30 billion. Prior to his retirement from the firm in 2018, Mr. Knight held leadership positions within Generation IM, notably developing and overseeing the firm’s U.S. business.

 

Prior to Generation, Mr. Knight was a Managing Director of Met West Financial, an LA based asset management company. Mr. Knight started his career at the Antitrust Division of the US Department of Justice. From 1977 to 1989, he served as the Chief of Staff to Representative and later Senator Al Gore. He served as the General Counsel of Medicis Pharmaceutical and then started his law practice in where he represented the International Olympic Committee, the US Olympic Committee, and numerous Fortune 500 Companies. Mr. Knight has also served in senior positions on four Presidential campaigns including serving as the Campaign Manager for President Clinton’s 1996 re-election campaign.

 

Mr. Knight has extensive board experience in both the for-profit and non-profit sectors. He served on a number of public company Boards including Medicis, Par Pharmaceutical, Entremed (Casi), Healthworld, Whitman Education, Comsat and the Schroder Mutual Fund Board complex. Mr. Knight currently serves on the Fund Boards of Generation Investment Management and on the Board of Gratitude Railroad. His philanthropic efforts include serving as Chair of the Climate Museum and the Board of Emergent, a nonprofit intermediary to help stop deforestation on tropical forest nations.

 

He received a BA from Cornell University and a JD from the Georgetown Law School.

Mohsin Y. Meghji is a Managing Partner of M-III Partners L.P., a New York-based merchant banking firm. He is a nationally recognized U.S. turnaround professional with an exemplary track record of accomplishment across a wide range of industries. His 25+ year career has focused primarily on maximizing value for stakeholders. He has accomplished this through management and/or advisory roles in partnership with some of the world’s leading financial institutions, private equity, and distressed hedge fund investors. Mr. Meghji serves as Chairman of the Board of Infrastructure & Energy Alternatives, Inc., one of the country’s leading renewables-focused engineering and construction firms, which merged with a SPAC sponsored by M-III Partners in March of 2018 and is now listed on the NASDAQ. Mr. Meghji’s most recent corporate role was as Executive Vice President & Head of Strategy at Springleaf Holdings, LLC as well as CEO of its captive insurance companies. Springleaf was listed on the NYSE in late 2013. Prior to Springleaf, Meghji co-founded Loughlin Meghji + Company, a financial advisory firm which became one of the leading restructuring boutiques in the U.S. Earlier in his career, Meghji spent 12+ years with Arthur Andersen & Co. in the firm’s London, Toronto, and New York offices as a Partner in the Global Corporate Finance group. He has served as a director on a number of corporate boards including Mariner Health Care Inc, Cascade Timberlands, LLC, Dan River, Inc., and MS Resorts. He is a director of the Equity Group International Foundation, which provides funding for underprivileged high potential students in Kenya. Previously, he served on the Boards of The Children’s Museum of Manhattan as well as HealthRight International from 2004 to 2012. Mr. Meghji is a graduate of the Schulich School of Business, York University, Canada and has taken executive courses at the INSEAD School of Business in France. He has previously qualified as a U.K. and Canadian Chartered Accountant as well as a U.S. Certified Turnaround Professional.

Stuart Diamond is the Global Chief Financial Officer for GroupM, the world’s leading media investment company responsible for over $50 billion in media investment through agencies Mindshare, MediaCom, Wavemaker, Essence and m/SIX, as well as the outcomes-driven programmatic audience company, Xaxis, LLC. Before joining GroupM, Mr. Diamond was a member of the WPP plc family as the CFO for Healthworld Corporation (now called Ogilvy Health), where he took the company public and negotiated its sale to Cordiant Communications Group in 2000. He also served as CFO for National Medical Health Card Systems, Inc., a comprehensive pharmacy benefit management company. From 2008 to 2014, Mr. Diamond was the CFO for GroupM North America, where he established financial strategies and supervised all corporate accounting and financial activities for GroupM and its agencies. Earlier in his career, he held the positions of Vice President and Controller for Calvin Klein, Inc and as Senior Vice President and CFO for Medicis Pharmaceutical Corporation. Mr. Diamond holds a B.S. from the State University of New York, a Master of Science, Taxation degree from Pace University, and an MBA from Fordham.

Ms. Zannes brings more than 30 years of executive-level management experience dedicated to defining and advancing company goals and overcoming obstacles impeding corporate success. Prior to her position at bioAffinity Technologies, Ms. Zannes founded The Zannes Firm focusing on strategic solutions for private industry in the medical, environmental and energy fields. In her current capacity as bioAffinity Technologies CEO and President, she has built a team of award-winning scientists and executives who are advancing breakthrough oncology-focused diagnostics and therapeutics.

 

Ms. Zannes was President of the Energy Recovery Council, the national trade group for the $10 billion waste-to-energy industry, and General Manager of ECOS Corporation, a subsidiary of Burlington Environmental. Ms. Zannes also served as a project manager at Wheelabrator Technologies, Inc. where she led project teams that developed, negotiated and financed the company’s renewable energy generation facilities. Ms. Zannes began her career as a journalist, working for Voice of America and the Associated Press. Before entering the business world, she served as a legislative aide specializing in energy policy and law for Congressman Charles Wilson (D-TX). She is licensed to practice law in New Mexico. She has been awarded Lifetime Achievement Awards by the American Society of Mechanical Engineers and the Earth Engineering Center Award from the WTE Council of Columbia University.

 

She is the co-founder of two engineering research centers at Columbia University. Ms. Zannes received her B.A. in Journalism from the University of New Mexico and her J.D. from the University of Puget Sound in Washington State.

Scientific & Medical Advisory Board

Principal Investigator at the University of North Carolina School of Medicine Center for
Environmental Medicine, Asthma and Lung Biology

 

Dr. Alexis focuses on the use of sputum as a primary sampling tool for measuring cellular, biochemical and genetic outcomes in the human airway.  Dr. Alexis is a leading expert in the use of flow cytometry in the analysis of sputum.

 

Assistant Professor of Medicine at Indiana University School of Medicine

 

Dr. Sears is a physician scientist with a focus on lung cancer whose laboratory focuses on the impact of DNA damage and repair on the development of smoking-related lung cancers and on treatment response.

Professor of Medicine and Lung Cancer Pulmonologist at the Medical University of South Carolina

 

Dr. Silvestri specializes in the evaluation, management and improvement of outcomes in lung cancer patients.  He has experience in evaluating new technologies for the diagnosis and staging of lung cancer. His research includes screening for lung cancer, how patients should be diagnosed and staged with the disease, and how to evaluate new technologies needed to diagnose and treat these patients.

Dr. Hill is a practicing pulmonary and critical care physician with Waterbury Pulmonary Associates and serves as their director of clinical research. He is a member of the Lung Association’s National Board of Directors and is the immediate past chair of the Northeast Regional Board of the American Lung Association. He serves on the Leadership Board of the American Lung Association in Connecticut and is a former chair of that board. He is an assistant clinical professor of medicine at the Yale University School of Medicine, an assistant clinical professor at the Frank Netter School of Medicine at Quinnipiac University, and a clinical instructor at the University of Connecticut School of Medicine. Dr. Hill attends at Waterbury Hospital and St Mary’s Hospital in Waterbury, CT and serves as the chair of the Pharmacy and Therapeutics Committee at Waterbury Hospital. He is the past president of the Connecticut Thoracic Society. He has been the principal investigator for more than 75 pulmonary research trials and the author of many papers.

Our Collaborations

Founded in 2000 by Madeleine Lemieux, PhD, Bioinfo specializes in high-throughput data analysis, mining, integration and visualization. Bioinfo provides bioAffinity Technologies with key insights and analysis of data and clinical results to advance the development and commercialization of the Company’s CyPath® test. Dr. Lemieux combines her training in computer science and stem cell biology to provide bioinformatics consulting services to clients. She works closely with the scientists at bioAffinity and The UT Health Science Center to better focus research on the CyPath® assay and support its commercialization.

Dykema is a leading national law firm serving business entities worldwide on a wide range of issues. Wilhelm Liebmann is bioAffinity’s external corporate counsel. Mr. Liebmann advises public and private companies on mergers and acquisitions, public offerings, private placements, joint ventures, and general corporate and partnership matters. He also counsels companies on corporate governance, financial reporting and disclosure, and SEC compliance issues. He is the leader of the firm’s Corporate Finance Practice Group in the Business Services Department. He represents clients in a variety of industries and has extensive experience working with government regulators to assist clients in structuring transactions in regulated industries.

Greenleaf Health LLC is a full-service regulatory consulting firm that provides strategic guidance to FDA-regulated companies that are developing innovative solutions to pressing public health challenges. bioAffinity Technologies is among a select group of clients in the healthcare sector seeking to advance breakthrough technologies that make a difference in the medical field. Daniel Schultz, MD, a former Director of the FDA’s Center for Devices and Radiological Health (CDRH), leads Greenleaf’s Medical Devices and Combination Products team. Together, these experts provide bioAffinity Technologies with strategic guidance on regulatory issues including pre-market review, product lifecycle management, manufacturing and compliance, and marketing and promotional practices within a rapidly changing regulatory environment.

Hyman, Phelps & McNamara is the largest dedicated FDA practice law firm in the country.  Founded in 1980, the firm was named the top FDA law firm by US News and World Report three years in a row.  In its medical devices and diagnostics practice area, Hyman, Phelps & McNamara helps clients understand all aspects of FDA’s regulation of medical device development, approval, clearance, manufacturing, post-market requirements, and marketing.  The firm works collaboratively with physicians and consultants to provide targeted medical and scientific expertise to help accomplish the regulatory goals of its clients.

As a leading contract research organization (CRO), Labcorp Drug Development provides comprehensive drug development solutions for a range of industries. Our services cover the preclinical, clinical and post-market phases of drug development, the product life cycles for medical device and diagnostics and development services. Labcorp Drug Development is a global leader in nonclinical safety assessment, clinical trial testing and clinical trial management services. Our unique perspectives are based on decades of scientific, medical and regulatory expertise. Together with our clients, we support the development of innovative, life-changing treatments.

Peacock Law LLC has served as intellectual property counsel to bioAffinity Technologies since the Company’s incorporation. The law firm has helped build bioAffinity’s strong U.S. and international patent portfolio in 22 countries, including the U.S., EU, Canada, Australia, Japan, Mexico, China and Japan. Collaboration with the law firm has led to more than 45 awarded patents and four patents pending, with enforceable rights extending to 2030.  bioAffinity’s patent counsel, Janeen Vilven-Doggett, Ph.D., brings a scientific background to her practice of law, guiding innovative products to the marketplace by protecting proprietary technologies. Peacock Law’s broad base of global connections has helped bioAffinity secure patent protection in all major markets.

bioAffinity Technologies works collaboratively with The University of Texas Health at San Antonio to advance research into the Company’s platform technology for the diagnosis and treatment of cancer.  One of the country’s leading health sciences universities, UT Health makes lives better with life-saving research, exceptional patient care and advanced academics in health care.   In addition to healthcare, education and community engagement, UT Health San Antonio champions research to develop life-saving advancements in treatment for cancer, aging and other serious conditions.  Its research facilities offer advanced equipment and services to provide researchers with the most advanced tools in the industry and provide patients with cutting-edge care.

 

https://www.uthscsa.edu/

UTSA’s Office of Commercialization and Innovation works with bioAffinity Technologies to provide the Company with critical resources including laboratories and equipment for the development and commercialization of its proprietary research. Established in 1969, UTSA is recognized today as a leading research university with robust programs in health, cybersecurity, energy, sustainability, and human and social development. The UTSA Office of Commercialization and Innovation focuses on research partnerships, intellectual property, proof-of-concept development, new venture incubation and entrepreneurial training to help promising new technologies reach their commercial market.

bioAffinity Technologies is proud to play a part in the University of Texas Health video highlighting our impressive research collaboration to uncover the mechanisms of cancer. The collaboration with the University of Texas, a leader in innovation, has led to exciting advancements. In this video, you’ll see physicians, scientists, and bioAffinity Technologies CEO Maria Zannes discuss how medical breakthroughs are being commercialized and made available to those who need them.